Discover why Altimmune (ALT) and Viking Therapeutics (VKTX) are top picks for high-risk investors. Click here to read my most ...

Eli Lilly is a global healthcare giant, generating strong growth from a diverse portfolio of blockbuster medications. Viking ...

The latest trading day saw Viking Therapeutics, Inc. (VKTX) settling at $26.61, representing a +1.88% change from its previous close.

In a report released today, Andy Hsieh from William Blair maintained a Buy rating on Viking Therapeutics (VKTX – Research Report). The company’s shares closed today at $26.61.

NVO advances obesity pipeline with CagriSema and Amycretin while expanding through major deals amid rising competition.

Financial Stability: Eli Lilly's balance sheet is more robust, with debt making up only 4% of equity, considerably less than ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

This feature is currently unavailable; we are sorry for the inconvenience to you. Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets ...

Nasdaq provides visual representation of analyst expected earnings growth. Read our earnings report guide before you consider the forecast information when making investment decisions. Visit the ...